Travere Therapeutics, Inc. TVTX Income from Continuing Ops
Income from Continuing Ops at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperations.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s income from continuing ops.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s income from continuing ops?
- Travere Therapeutics, Inc. (TVTX) reported income from continuing ops of -$36.6M in Q1 2026.
- How has Travere Therapeutics, Inc.'s income from continuing ops changed year-over-year?
- Travere Therapeutics, Inc.'s income from continuing ops increased by 11.2% year-over-year, from -$41.23M to -$36.6M.
- What is the long-term trend for Travere Therapeutics, Inc.'s income from continuing ops?
- Over 2 years (2021 to 2023), Travere Therapeutics, Inc.'s income from continuing ops has grown at a 725604.8% compound annual growth rate (CAGR), from -$3.63 to -$191.17M.
- What does income from continuing ops mean?
- Net income from business operations that are expected to continue, excluding gains or losses from discontinued segments. The best measure of ongoing earning power.